Pacific Biosciences of California, ... (PACB)
|52 Week Range||3.85-14.2|
|1y Target Est||-|
|DCF Unlevered||PACB DCF ->|
|DCF Levered||PACB LDCF ->|
|Debt / Equity||213.92%||Strong Buy|
Upgrades & Downgrades
Latest PACB news
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
15 March 2023
PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.
PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top
17 February 2023
Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
16 February 2023
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California, Inc. (PACB) Q4 2022 Earnings Call Transcript
16 February 2023
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Todd Friedman - Director, Investor Relations Christian Henry -...
Jackson Square Partners Cuts Stake in Pacific Biosciences of California
10 February 2023
Fintel reports that Jackson Square Partners has filed a 13G/A form with the SEC disclosing ownership of 15.01MM shares of Pacific Biosciences of California Inc (PACB).
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled Th...
10 February 2023
These cutting-edge biotech companies quickly fell out of favor with investors this week.
Illumina, Pacific Biosciences, And Oxford Nanopore Market Position Comparison
6 February 2023
The gene sequencing market is ripe for disruption. ILMN suffers from multiple strategic setbacks that will likely impact margins for years.
Cathie Wood Is Crushing It This Year Thanks To 9 Stocks
20 January 2023
Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.
Why Pacific Biosciences Of California Shares Are Trading Higher Today - Pacific Biosciences (NASDAQ:...
9 January 2023
Pacific Biosciences of California (PacBio) PACB shares are trading higher today after the company announced it received orders for 76 Revio systems in the fourth quarter of 2022. The company also issu...
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >